Diligence memo · auto-generated · as of July 2, 2026

Exxel Pharma, INC.

Exxel Pharma, INC. looks fair against its niche peers and is quiet on financing cadence.

Diligence furtherNo decisive signal either way from the public record alone — the call needs primary diligence beyond the filings.

Businessfiled

Exxel Pharma, INC. operates in Biotechnology, based in Aurora.

Sub-sector tags: pharma.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

Exxel Pharma, INC. has raised $600K in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Pre-Seed (a round under $1.0M).

Largest single filing: $600K on 2024-11-20.

Most recent recorded round closed around 2024-11-20.

Valuation (modeled)modeled

Provath models Exxel Pharma, INC. at approximately $2.2M (range $320K–$6.5M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Fair. Modeled value is 0.68× the median modeled value of Pre-Seed Biotechnology companies in 2022–2024 (185 peers) — value vs value, same stage and era. Within the normal band (68% of peer median) for its niche.

Financing rhythm & timingmixed

Last raise 19 mo ago; this sector typically re-raises about every 14 months.

Slightly overdue versus sector cadence.

Comparablesmixed

Capital scale ranks ahead of 13% of Biotechnology peers (4293 compared).

Modeled value ranks above 5% of those peers.

Closest niche peers: TissueMill Technologies LLC, Aldebaran Therapeutics, Inc., BullFrog AI Holdings, Inc., Vesicle Therapeutics Inc., TAUC3 Biologics Ltd.

Peoplefiled

2 named people on file across officers, directors and signatories.

Risks & flagsmixed

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.